ArticleTranslational cancer research2021
The role of NLRP3 in the prognosis and immune infiltrates of skin cutaneous melanoma (SKCM).
Article in Translational cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 12 citations in OpenAlex.
- YIF1B Mutational Dysregulation Drives Cutaneous Melanoma Progression by Remodeling the TME.Human mutation · 2026Article
- Exosomes as key mediators in immune and cancer cell interactions: insights in melanoma progression and therapy.Archives of dermatological research · 2025Review
- Investigation of GPR143 as a promising novel marker for the progression of skin cutaneous melanoma through bioinformatic analyses and cell experiments.Apoptosis : an international journal on programmed cell death · 2024Article
- Decreased survival in patients with pancreatic cancer may be associated with an increase in histopathological expression of inflammasome marker NLRP3.Histology and histopathology · 2024Article
- Divergent functions of NLRP3 inflammasomes in cancer: a review.Cell communication and signaling : CCS · 2023Review
- The NLRP3 inflammasome - interleukin 1β axis in uveal melanoma.FEBS open bio · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSkin cutaneous melanoma is one of the most aggressive types of cancers worldwide. Therefore, the identification of skin cutaneous melanoma (SKCM) biomarkers is of great importance. NLRP3 inflammasome complex nodelike receptor protein 3 (NLRP3) is one of the most characteristic inflammasomes belonging to the NLR protein family. This is the first time to use TCGA data to study NLRP3 expression in SKCM patients and its prognostic value, potential biological function, and impact on the immune system.
methodsThe expression of NLRP3 in SKCM was analyzed by Gene Expression Profiling Interactive Analysis (GEPIA). We assessed the impact of NLRP3 on SKCM patient survival through the survival module and then downloaded the SKCM data set from TCGA. Logistic regression was used to analyze the correlation between clinical data and NLRP3 expression. Univariate survival rate and multivariate Cox analysis were used to compare several clinical features and survival rates. We also used CIBERSORT to investigate the association between NLRP3 and cancer immune infiltration. We used TIMER to investigate NLRP3 expression and collection of immune infiltration levels in SKCM, as well as cumulative survival in SKCM. Gene set enrichment analysis (GSEA) was performed using the TCGA dataset. Besides, data from The Human Protein Atlas (HPA) was used to validate the results.
resultsUnivariate Logistic regression analysis showed that increased NLRP3 expression was significantly correlated with age, stage, and tumor status. Specifically, NLRP3 expression level had significant positive correlations with infiltrating levels of B cell, CD4+ T cells, CD8+ T cells, Macrophages, Neutrophils, and DCs in SKCM. GSEA revealed that NLRP3 was closely correlated with pathways in cancer. HPA showed that in tumor tissues, NLRP3 had higher levels of expression compared to normal tissues.
conclusionsThe discovery of NLRP3 as a new biomarker of SKCM helps to elucidate how changes in the immune environment promote the occurrence of cutaneous melanoma. Further analysis suggested that NLRP3 might be a predictor of SKCM prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.